According to Gram Research analysis, scientists discovered that blocking a protein called ZDHHC17 stops cancer cells from dividing and helps the immune system fight tumors more effectively. In laboratory and mouse studies, blocking ZDHHC17 reduced tumor growth and increased cancer cell visibility to immune cells. The research suggests combining existing CDK4-blocking drugs with immunotherapy could overcome resistance in cancers with high ZDHHC17 levels, though human trials are needed to confirm this approach.
Scientists discovered that a protein called ZDHHC17 helps cancer cells divide and grow by adding fat molecules to another protein called CDK4. When researchers blocked this process in lab studies and mice, tumors stopped growing and cancer cells couldn’t escape the immune system. The study suggests combining existing cancer drugs that target CDK4 with immunotherapy drugs could be more effective against certain cancers. This finding opens a new way to fight cancers that don’t respond well to current immune-boosting treatments.
Key Statistics
A 2026 research article published in Advanced Science found that blocking ZDHHC17-mediated palmitoylation of CDK4 led to profound cell cycle arrest and suppressed tumor growth in laboratory and mouse models.
According to the 2026 study, high ZDHHC17 expression was positively correlated with non-response to anti-PD-1 immunotherapy in cancer patients, suggesting this protein may predict treatment resistance.
The research demonstrated that Zdhhc17-depletion reduced both cell cycle progression and immune response suppression in mice fed high-fat diets, indicating diet influences this cancer pathway.
The Quick Take
- What they studied: How a protein called ZDHHC17 helps cancer cells divide faster by attaching fat molecules to another protein, and whether blocking this process could stop cancer growth
- Who participated: Laboratory cancer cells, mice fed high-fat diets, and data from cancer patients receiving immunotherapy treatments
- Key finding: Blocking ZDHHC17 or the fat-attachment process stopped cancer cells from dividing and made tumors smaller in mice, while also helping the immune system fight cancer better
- What it means for you: This research suggests doctors might combine existing CDK4-blocking drugs with immune checkpoint inhibitor drugs to treat certain cancers more effectively, though human trials are still needed to confirm this approach works safely
The Research Details
Researchers conducted laboratory experiments using cancer cells and mouse models to understand how ZDHHC17 works. They used a chemical called 2-bromohexadecanoic acid (2-BP) to block the fat-attachment process and compared results to normal conditions. They also studied mice eating high-fat diets to see how diet affects this protein’s role in cancer. Finally, they analyzed data from cancer patients to see if ZDHHC17 levels predicted which patients wouldn’t respond well to immune-boosting cancer drugs.
The team used multiple approaches to understand the mechanism: they removed the ZDHHC17 gene from cells, blocked the fat-attachment process chemically, and tracked how these changes affected cancer cell division and immune response. They measured cancer cell growth, tumor size in mice, and immune system activity to evaluate their findings.
This research approach is important because it connects three separate biological processes—fat attachment to proteins, protein modification, and cancer cell division—into one pathway. Understanding how these pieces work together helps scientists design better combination treatments. The use of both lab cells and living mice provides stronger evidence than either approach alone, and including patient data shows the findings might apply to real cancer cases.
This research was published in Advanced Science, a peer-reviewed scientific journal. The study used multiple experimental methods to confirm findings, which strengthens confidence in the results. However, the research was conducted primarily in laboratory settings and mice, not yet in human patients, so results may not directly translate to clinical practice. The specific sample sizes for human patient data were not detailed in the abstract, which limits assessment of that portion’s reliability.
What the Results Show
When researchers blocked ZDHHC17 or the fat-attachment process it controls, cancer cells stopped dividing and tumors grew much smaller in mice. This happened because blocking ZDHHC17 reduced the activity of CDK4, a protein that acts like an accelerator for cell division. The effect was particularly strong when researchers also blocked another modification process called ubiquitination, suggesting these two processes work together to drive cancer cell growth.
In mice eating high-fat diets, removing ZDHHC17 slowed cancer cell division and reduced immune system suppression. This is important because cancer cells often hide from the immune system by producing a protein called PD-L1. When ZDHHC17 was blocked, cancer cells produced less PD-L1, making them more visible to immune cells.
The clinical analysis revealed that cancer patients with high ZDHHC17 levels were less likely to respond to anti-PD-1 immunotherapy drugs. This suggests ZDHHC17 is one reason some patients don’t benefit from these treatments. The researchers propose that combining CDK4 inhibitor drugs (which already exist) with immune checkpoint blocker drugs could overcome this resistance.
The research identified that ZDHHC17 adds fat molecules specifically to CDK4, and this fat attachment is necessary for CDK4 to work properly with cyclin D1, another protein involved in cell division. The study also showed that a protein called TRAF6 modifies CDK4 in a way that works together with ZDHHC17’s fat attachment. When either the fat attachment or TRAF6’s modification was blocked, CDK4 became much less active.
Previous research established that CDK4 is important for cancer cell division, leading to the development of CDK4 inhibitor drugs. This study builds on that knowledge by explaining exactly how ZDHHC17 helps CDK4 function. The connection between fat attachment (palmitoylation) and cancer is relatively new, with most previous research focusing on genetic mutations. This work suggests that how proteins are modified after they’re made—not just their genetic code—is crucial for cancer development. The finding that high ZDHHC17 predicts poor response to immunotherapy is novel and could help doctors choose better treatment combinations.
This research was primarily conducted in laboratory cells and mice, not in human patients, so results may not work exactly the same way in people. The study didn’t test the proposed combination treatment (CDK4 inhibitors plus immunotherapy) in living animals or humans, so effectiveness in real patients remains unknown. The analysis of patient data was observational, meaning researchers looked at existing data rather than randomly assigning patients to different treatments, which limits the strength of conclusions. The specific number of cancer patients analyzed wasn’t clearly stated. Additionally, the research focused on specific types of cancer cells in the lab, so findings may not apply equally to all cancer types.
The Bottom Line
Based on this research, doctors might consider combining CDK4 inhibitor drugs with immune checkpoint blocker drugs for patients with high ZDHHC17 expression, though this combination approach still needs testing in human clinical trials. Patients with cancers that don’t respond to immunotherapy alone should discuss with their oncologist whether testing for ZDHHC17 levels might help guide treatment choices. This is a moderate-confidence recommendation based on strong laboratory evidence but limited human data.
Cancer patients, especially those with tumors that haven’t responded to immunotherapy drugs, should be aware of this research as it may lead to better treatment options. Oncologists treating patients with immune-resistant cancers should follow this research as it develops toward clinical trials. Patients eating high-fat diets should note that diet appears to influence this cancer pathway, though more research is needed. People without cancer should not take action based on this research, as it targets advanced disease treatment.
If this research leads to clinical trials, it typically takes 3-7 years to test combination treatments in human patients and get regulatory approval. Patients currently in treatment won’t see immediate changes, but this research could influence treatment recommendations within 2-5 years if human trials confirm the findings. Any benefits from this approach would likely appear within weeks to months of starting the combination treatment, similar to current immunotherapy timelines.
Frequently Asked Questions
What is ZDHHC17 and why does it matter for cancer treatment?
ZDHHC17 is a protein that helps cancer cells divide faster by attaching fat molecules to another protein called CDK4. Blocking ZDHHC17 stops cancer cell division and helps the immune system fight tumors, making it a potential new treatment target for cancers resistant to current immunotherapy drugs.
Can blocking ZDHHC17 help patients who don’t respond to immunotherapy?
Research shows high ZDHHC17 levels predict poor response to immunotherapy. Combining CDK4 inhibitor drugs with immunotherapy might overcome this resistance, but this combination approach has only been tested in labs and mice so far, not yet in human patients.
Does eating a high-fat diet affect ZDHHC17 and cancer risk?
In mice, high-fat diets appeared to increase ZDHHC17’s cancer-promoting effects. However, this research was conducted in animals, not humans, so it’s unclear whether diet directly affects ZDHHC17 in people or cancer development risk.
When will this research lead to new cancer treatments?
The proposed combination treatment (CDK4 inhibitors plus immunotherapy) still needs human clinical trials, which typically take 3-7 years. If trials succeed, new treatment recommendations could emerge within 2-5 years, though individual patient access may vary.
Should cancer patients get tested for ZDHHC17 levels now?
ZDHHC17 testing is not yet standard practice. Patients with immunotherapy-resistant cancers should discuss with their oncologist whether testing might help guide treatment, but this remains an emerging research area rather than established clinical practice.
Want to Apply This Research?
- Users with cancer diagnoses could track ZDHHC17 test results and CDK4 inhibitor medication adherence, noting dates when tests were performed and dosages taken, to monitor whether their treatment plan aligns with this emerging research
- Users could set reminders to discuss ZDHHC17 testing with their oncologist at the next appointment and request information about combination CDK4 inhibitor and immunotherapy trials they might qualify for
- Long-term tracking could include recording tumor response assessments, immunotherapy response markers, and any new treatment recommendations from oncologists, helping users and doctors identify patterns in how this emerging research applies to their specific case
This research describes laboratory and animal studies that have not yet been tested in human clinical trials. The proposed combination treatment approach is experimental and not yet approved for clinical use. Cancer patients should not change their treatment plans based on this research alone. All cancer treatment decisions should be made in consultation with qualified oncologists who can evaluate individual patient circumstances, existing treatment options, and clinical trial availability. This article is for informational purposes and should not be considered medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.